drugset / Trial / NCT06947109
A Clinical Study of AK139 in Healthy Subjects
RandomizedParallel-groupDouble-blindTreatment
Summary
This is a phase I clinical study on dose escalation evaluating the safety, tolerability, PK and PD of a single dose of AK139 administered subcutaneously in healthy subjects.
Timeline
- Start
- 2025-05-06
- Primary completion
- 2026-01-30
- Completion
- 2026-01-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | GUMOKIMAB | Monoclonal antibody | — | Subcutaneous |
Indications
No indication recorded.